Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Viridian Therapeutics, Inc.\DE (VRDN) Enterprise Value: 2014-2025

Historic Enterprise Value for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Sep 2025 value amounting to $1.3 billion.

  • Viridian Therapeutics, Inc.\DE's Enterprise Value rose 81.56% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$646.2 million, marking a year-over-year increase of 32.80%. This contributed to the annual value of $800.9 million for FY2024, which is 19.91% up from last year.
  • According to the latest figures from Q3 2025, Viridian Therapeutics, Inc.\DE's Enterprise Value is $1.3 billion, which was up 120.23% from $577.3 million recorded in Q2 2025.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Enterprise Value registered a high of $1.3 billion during Q3 2025, and its lowest value of -$56.1 million during Q3 2021.
  • Moreover, its 3-year median value for Enterprise Value was $668.0 million (2023), whereas its average is $635.5 million.
  • Its Enterprise Value has fluctuated over the past 5 years, first slumped by 506.73% in 2021, then skyrocketed by 8,055.02% in 2022.
  • Quarterly analysis of 5 years shows Viridian Therapeutics, Inc.\DE's Enterprise Value stood at $232.5 million in 2021, then spiked by 223.07% to $751.1 million in 2022, then declined by 11.07% to $668.0 million in 2023, then grew by 19.91% to $800.9 million in 2024, then skyrocketed by 81.56% to $1.3 billion in 2025.
  • Its Enterprise Value was $1.3 billion in Q3 2025, compared to $577.3 million in Q2 2025 and $461.8 million in Q1 2025.